Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1469-1478

  Wang, Zhiyu ^a   Wang, Juan ^a   Li, Xing ^a   Xing, Lianping ^b   Ding, Yan ^a   Shi, Penghui ^a   Zhang, Yuehua ^a   Guo, Shenghu ^a   Shu, Xin ^c   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Bone metastasis; Bortezomib; Proliferation; Prostate cancer; Smad ubiquitination regulatory factors; Ubiquitin ligase E3; WW domain containing E3 ubiquitin protein ligase 1

Indexed keywords

BORTEZOMIB; MESSENGER RNA; UBIQUITIN LIGASE SMURF1; UBIQUITIN LIGASE SMURF2; UBIQUITIN LIGASE WWP1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; SMURF1 PROTEIN, HUMAN; SMURF2 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; WWP1 PROTEIN, HUMAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PREVENTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOLID TUMOR; TREATMENT OUTCOME; BONE TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BORONIC ACIDS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PYRAZINES; UBIQUITIN-PROTEIN LIGASES;

EID: 84907464381     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2545     Document Type: Article

References (33)

1. Obertova Z, Brown C, Holmes M and Lawrenson R: Prostate cancer incidence and mortality in rural men - a systematic review of the literature. Rural Remote Health 12: 2039, 2012.
2. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104, 2008.
3. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P and van der Pluijm G: TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24: 609-617, 2007. (Pubitemid 50003597)
4. Whang PG, Gamradt SC, Gates JJ and Lieberman JR: Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer Prostatic Dis 8: 327-334, 2005. (Pubitemid 43078167)
5. Satoh F, Mimata H, Nomura T, et al: Autocrine expression of neurotrophins and their receptors in prostate cancer. Int J Urol 8: S28-S34, 2001. (Pubitemid 34225134)
6. Festuccia C, Gravina GL, Muzi P, et al: In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 67: 1255-1264, 2007. (Pubitemid 47435773)
7. Hellwinkel OJ, Asong LE, Rogmann JP, et al: Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma. Prostate Cancer Prostatic Dis 14: 38-45, 2011.
8. Garrett IR, Chen D, Gutierrez G, et al: Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111: 1771-1782, 2003. (Pubitemid 38057757)
9. Micel LN, Tentler JJ, Smith PG and Eckhardt GS: Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 31: 1231-1238, 2013.
10. Yang B and Kumar S: Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ 17: 68-77, 2010.
11. Farooqi AA, Waseem MS, Riaz AM and Bhatti S: SMURF and NEDD4: sharp shooters monitor the gate keepers and ion traffic controllers of lead astray cell. J Membr Biol 244: 1-8, 2011.
12. Chen C, Sun X, Guo P, et al: Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26: 2386-2394, 2007. (Pubitemid 46572813)
13. Papandreou CN and Logothetis CJ: Bortezomib as a potential treatment for prostate cancer. Cancer Res 64: 5036-5043, 2004. (Pubitemid 39006513)
14. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999. (Pubitemid 29269108)
15. Sunwoo JB, Chen Z, Dong G, et al: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001. (Pubitemid 32708698)
16. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C and McConkey DJ: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2: 835-843, 2003.
17. Uy GL, Trivedi R, Peles S, et al: Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma 7: 587-589, 2007.
18. Oyajobi BO, Garrett IR, Gupta A, et al: Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 139: 434-438, 2007. (Pubitemid 47512190)
19. Giuliani N, Morandi F, Tagliaferri S, et al: The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110: 334-338, 2007. (Pubitemid 47026851)
20. Alaaeddine N, De Montigny C and Sadouk M: Real-time reverse transcription-polymerase chain reaction quantification of tumor necrosis factor alpha messenger in human leukocytes. Clin Lab 57: 799-802, 2011.
21. Zhu Y, Li T, Song J, et al: The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling. Basic Res Cardiol 106: 787-799, 2011.
22. Weeraratna AT, Dalrymple SL, Lamb JC, et al: Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 7: 2237-2245, 2001. (Pubitemid 32751620)
23. Chen C and Matesic LE: The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 26: 587-604, 2007. (Pubitemid 350119775)
24. Rieser E, Cordier SM and Walczak H: Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem Sci 38: 94-102, 2013.
25. Bernassola F, Karin M, Ciechanover A and Melino G: The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14: 10-21, 2008. (Pubitemid 351885498)
26. Murakami G, Watabe T, Takaoka K, Miyazono K and Imamura T: Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14: 2809-2817, 2003. (Pubitemid 36871523)
27. Severe N, Dieudonne FX and Marie PJ: E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis 4: e463, 2013.
28. Jones DC, Wein MN, Oukka M, Hofstaetter JG, Glimcher MJ and Glimcher LH: Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science 312: 1223-1227, 2006. (Pubitemid 43801150)
29. Zhao L, Huang J, Zhang H, et al: Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells 29: 1601-1610, 2011.
30. Sterz J, von Metzler I, Hahne JC, et al: The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 17: 879-895, 2008. (Pubitemid 351864325)
31. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144, 2003. (Pubitemid 36323723)
32. Kane RC, Farrell AT, Sridhara R and Pazdur R: United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12: 2955-2960, 2006. (Pubitemid 43837337)
33. Qiang YW, Hu B, Chen Y, et al: Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113: 4319-4330, 2009.